JEMPERLI (dostarlimab-gxly) injection

BLA 761174
Drug Name: JEMPERLI
Active Ingredient: DOSTARLIMABGXLY
Company: GLAXOSMITHKLINE LLC
Approval Date: 31-Jul-2023
Dosage Forms And Strengths: Injection: 500 mg/10 mL (50 mg/mL) solution in a single-dose vial.
FDA-approved use on approval date: In combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA approved test, or microsatellite instability-high (MSI-H)

Request JEMPERLI (dostarlimab-gxly) Communication – Important Information
If JEMPERLI (dostarlimab-gxly) is not available in your country, and you require assistance to get access this medication under “Named Patient Program (NPP)” treatment in the following city of India – Bengaluru, Delhi, Chennai, Hyderabad, Mumbai, Pune, Kolkata, Ahmedabad, Gurgaon, please send us a formal request for communication regarding this medication at urgent@cancermedicinesnetwork.com or call a customer support or WhatsApp your query

Please Note:
JEMPERLI (dostarlimab-gxly) is a prescription medication. A valid prescription from a licensed healthcare provider is required for any request.

JEMPERLI (dostarlimab-gxly) injection

Get In Touch

Get in touch with us at Verve Biscience, and one of our team will be on hand to help with any queries you may have.

The Verve Biscience is open
Monday to Saturday.
Business hours: 10.00 A.M to 06.00 P.M.

Contact Number:
M:+91-9910645395

Email ID:
info@cancermedicinesnetwork.com
rakeshkhanna.rk@gmail.com

Description

Dostarlimab has been approved to treat specific cancers in various jurisdictions. Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as an anti-cancer medication for the treatment of endometrial cancer. Dostarlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody.

The most common side effects reported in the US include fatigue/asthenia, nausea, diarrhea, anemia, and constipation. Additional side effects reported in the European Union include vomiting, joint pain, itching, rash, fever, and hypothyroidism (low levels of thyroid hormones).

JEMPERLI (dostarlimab-gxly) injection, for intravenous use Initial U.S. Approval: 2021

See full prescribing information : Click Here

How to get access JEMPERLI (dostarlimab-gxly) for personal use ?

To get access to JEMPERLI (dostarlimab-gxly), you need a prescription from a doctor, as it is a prescription-only medication. Your prescription will be filled through a specialty pharmacy, which will handle insurance and coordinate delivery of the medication to you. Your doctor will also need to provide specific information for the prescription to be filled correctly.

However, patients in India can legally access it through the provision called the Named Patient Program (NPP). JEMPERLI (dostarlimab-gxly) prices may fluctuate over time because of market dynamics and regulatory changes. It can be imported for personal use under “Named Patient Program” treatment in multiple countries, including the Singapore, Kuala Lumpur (Malaysia), Bangkok (Thailand), Jakarta, Surabaya, Bandung (Indonesia), Manila, Cebu (Philippines), Ho Chi Minh City, Hanoi (Vietnam), Yangon (Myanmar), Phnom Penh (Cambodia), Vientiane (Laos), UAE, Saudi Arabia, Argentina, Brazil, UK, Hungary, Ireland, Latvia, Slovakia, Czech Republic, Belgium, Lithuania, Greece, Spain, Zimbabwe, Australia, and New Zealand.

To order or inquire about JEMPERLI (dostarlimab-gxly) international access, you can contact Verve Biosciences – a trusted pharmaceutical exporter, supplier, and distributor of anti-cancer and specialty medications.

📧 Email: urgent@cancermedicinesnetwork.com
📞 Call or WhatsApp: 9910645395 or 9910645395

Note: Availability may vary by country and is subject to regulatory approvals.

Delivered Countries

Serving over 65 countries worldwide with reliable pharmaceutical shipping across Asia-Pacific, Africa, Europe, the Middle East, North and South America.

North & South America: Canada, US, Mexico, Guatemala, El Salvador, Honduras, Costa Rica, Nicaragua, Panama, Cuba, Dominican Republic, Venezuela, Brazil, Bolivia, Chile, Peru, Ecuador Argentina, Columbia etc.
Europe (Germany, UK, France, Italy, Russia and Turkey etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
Middle East (Saudi Arabia, UAE, Egypt)
Africa: Ghana, Burkina, Togo, Benin, Nigeria, Nigeria, Cameroon, Sudan, Eritrea, Ethiopia, Somalia, Republic of Congo, (Democratic Republic of) Congo, Uganda, Kenya, Rwanda, Burundi, Tanzania, Zambia, Mozambique, Namibia, Botswana, Zimbabwe, South Africa.

About Healthcare Consultant

Rakesh brings an experience of 37 years in the pharmaceutical industry at various roles and responsibilities in Indian and US pharma MNCs. His areas of operations have been India and Southeast Asia, and he has been running a successful pharma business since 2010.

Testimonials

Dear Rakesh and Colleagues, We are very happy to let you know that, just after three weeks, there is no trace of the sickness anymore: your medicine did the job very well! We will always remember with great pleasure your warm welcoming in Delhi! We would like to thank you very much and wish you all the best. In the coming future we will be delighted to suggest your company to other patients. Best Regard.
Maria Cristina,Pier and Marcantonio Savelli
Maria Cristina,Pier and Marcantonio SavelliItaly
Sir, As a first time buyer of an iported drug I'm imressed with your company in procurement of the drug from Canada through the shipping time of 11 to 12 days is quite long to wait. Mr Rajesh Kanan your coordinator has been very helpful and cooperative to my many queries. He is always responsive to my SMS, Whatsapp, email and phone calls. Hoping that the good trend will continue in the future. There is some miscommunications with the TNT courier with my first delivery. Hope that will be solved in the second delivery. Best regards,
Dr. Steven
Dr. Steven

Frequently Asked Questions (FAQs)

No. At present. This medicine is not approved by the Drug Controller General Of India (DCGI).

It is a prescription medicine. You should have a VALID and RECENT Prescription.

No, we do not sell rather we just FACILITATE the Procurement of this Medicine in India

Yes, We do. Since we facilitate the Procurement of Medicines directly from the International companies and that too with all Legal Documents like International Comp. Invoice, Air Way Bill (AWB) and Bill Of Entry (BOE), we Guarantee for it.

It would take you 12-17 Working Days as it requires Govt Approvals/Certificates and coordination with an International company.

A detailed answer to provide information about your business, build trust with potential customers, or help the visitor with a problem they may be encountering

A detailed answer to provide information about your business, build trust with potential customers, or help the visitor with a problem they may be encountering

We are 24 Hours * 7 Days Available through our Website and Mobile Numbers?

Related Products

Category